

## WHAT IS CLAIMED IS:


1	
2	1. A mathod of evaluating a protein kinase C (PKC) activity in a tissue other than
3	monocytes of a subject, the method comprising:
4	evaluating the level of the PKC activity in monocytes of the subject,
5	the evel of PKC activity in the monocytes being correlated to the level of PKC
6	activity in a tissue other than monocytes.
7	
8	2. The method of claim 1, wherein the PKC activity is PKC $\beta$ activity.
ghi.	
o Kil	3. The method of claim 1, wherein the tissue is cardiovascular tissue.
·1 <u></u>	
12 <mark>   </mark>	4. The method of claim 3, wherein the cardiovascular tissue is retinal, kidney or aorta
1   1   1   2   3   2   4   4   4   2   3   3   4   4   5   3   5   5   5   5   5   5   5   5	vascular tissue or heart.
14	\ <b>\</b>
15	5. The method of claim 1, wherein the subject is a human.
16 <del></del>	
7	6. The method of claim 1, wherein the subject is an experimental animal.
18	
19≕≐	7. A method of determining if a subject is at risk for or has a PKC related disorder, the
20	method comprising:
21	evaluating the level of PKC activity in monocytes of the subject;
22	optionally comparing the level of the PKC activity in monocytes of the subject
23	with a standard,
24	thereby determining if the subject has a symptom of a PKC related disorder.
25	
26	8. The method of claim 7, wherein the PKC activity is PKC β activity.
27	
28	9. The method of claim 7, wherein the disorder is diabetes.
29	
30	10. The method of claim 7, wherein the disorder is diabetic retinonathy.

diabetic retinopathy, diabetic nephropathy, microalbumiuria, proteinuria, renal failure,

60

61	hypertension, atherosclerosis, coronary artery spasm, congestive heart failure, coronary artery
62	disease, valvular disease, arrhythmias, or cardiomyopathy.
63	
64	20. The method of claim 16, wherein the PKC activity is PKC β activity.
65	
66	21. The method of claim 16, wherein the subject is a human.
67	
1/180	22. The method of claim 16, wherein the subject is an experimental animal.
79000	23. A method of evaluating the effect of a treatment for a PKC related disorder on a
71	subject comprising:
72	administering a treatment for a PKC related disorder to a subject; and
73 <u>—</u>	evaluating the level of a PKC activity in monocytes of the subject, thereby evaluating the
74	effect of the treatment.
75 <b>U</b>	
72 73 73 75 76 77 78 77 78 77 78 77 78 77 78 77 78 78	24. The method of claim 23, wherein the disorder is diabetes.
7 <i>7</i> .	
78 <b>T</b> U	25. The method of claim 23, wherein the disorder is a cardiovascular disorder.
79 .	
80=	26. The method of claim 23, wherein the disorder is diabetes mellitus, Type I diabetes,
<b>⊭≟</b> 81	Type II diabetes, diabetic retinopathy, proliferative diabetic retinopathy, non-proliferative
82	diabetic retinopathy, diabetic nephropathy, microalbumiuria, proteinuria, renal failure,
83	hypertension, atherosclerosis, coronary artery spasm, congestive heart failure, coronary artery
84	disease, valvular disease, arrhythmias, or cardiomyopathy.
85	disease, varvatar disease, army ammas, or eardiomy opamy.
86	27. The method of claim 23, wherein the PKC activity is PKC β activity.
	27. The method of claim 23, wherein the TRC activity is TRC p activity.
87	28. The weekend of alsing 22 and a singular multipations have
88	28. The method of claim 23, wherein the subject is a human.
89	
90	29. The method of claim 23, wherein the subject is an experimental animal.
91	

92	30. A method of identifying a compound for the treatment of a PKC related disorder in a
93	subject, the method comprising:
94	administering a test compound for the treatment of the disorder to the subject; and
95	evaluating a PKC activity in monocytes of the subject,
96	the level of PKC activity being correlated with the effect of the treatment on the
97	disorder.
98	
99	31. The method of claim 30, wherein the disorder is diabetes.
100	- Pin
105/10	32. The method of claim 30, wherein the disorder is a cardiovascular disorder.
102	Caner, / V
103	33. The method of claim 30, wherein the PKC related disorder is diabetes mellitus, Type
104	I diabetes, Type II diabetes, diabetic retinopathy, proliferative diabetic retinopathy, non-
105	proliferative diabetic retinopathy, diabetic nephropathy, microalbumiuria, proteinuria, renal
106	failure, hypertension, atherosclerosis, coronary artery spasm, congestive heart failure, coronary
107	artery disease, valvular disease, arrhythmias, or cardiomyopathy.
103   104   105   106   107   108   109   110	
109	34. The method of claim $\S 0$ , wherein the PKC activity is PKC $\beta$ activity.
110	
11	35. The method of claim 30 further comprising:
112	optionally identifying a subject in need of a treatment for the disorder;
113	optionally evaluating a PKC activity in monocytes of the subject; and
114	comparing the PKC activity before the administration of the test compound to the
115	PKC activity after administration of the test compound,
116	wherein a compound for the treatment of the disorder is identified when the PKC
117	activity after the administration of the compound is altered compared to a standard.
118	
119	36. The method of claim 30, wherein the subject is a human.
120	
121	37. The method of claim 30, wherein the subject is an experimental animal.
122	•



	•
123	38. A method of identifying a compound for the treatment of aging or an aging-related
124	disorder in a subject, the method comprising:
125	administering a test compound for the treatment of aging or an aging-related
126	disorder to the subject; and
127	evaluating a PKC activity in monocytes of the subject,
12 <b>85))</b> 129	the level of PKC activity being correlated with the effect of the treatment on the
130	Oursorder.
131	39. A method of evaluating the effect of a treatment for aging or an aging-related
132	disorder on a subject comprising:
133	administering a treatment for aging or an aging-related disorder to a subject; and
134	evaluating the level of a PKC activity in monocytes of the subject, thereby evaluating the
135	effect of the treatment.
136	· ·
137	
1350171101 136171101 13814 11011101	
g 1. s.	
T	
NJ Li	
ļada da	